☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Jazz Pharmaceuticals
Jazz Pharmaceuticals Reports Acquisition of Redx Pharma’s KRAS Inhibitor Program
February 8, 2024
Jazz Pharmaceuticals Enters into a 5-Year Research Collaboration Agreement with MD Anderson Cancer Center to Study Zanidatamab in...
November 8, 2023
Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value
March 29, 2023
Jazz Pharmaceuticals’ Epidyolex (cannabidiol) Receives NICE Recommendation for the Reimbursement to Treat Seizures in England
February 1, 2023
Jazz Pharmaceuticals Exercised its Option to Advance Zymeworks' Zanidatamab for Cancer Patients
December 22, 2022
Michael G. Chez and Greg Grunberg Share Insights from “The Care Giver” Series Based on Epilepsy
August 22, 2022
Load more...
Back to Home